Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α

REFERENCES

• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–2441.
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S, . Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328(25):1797–1801.
   PubMed Web of Science ®Google Scholar
• Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol. 2010;9:119–122.
   Google Scholar
• Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: Challenges and advancements in management. J Am Med Assoc. 2011;306(3):294–301.
   Google Scholar
• Ghany MG, Strader DB, Thomas DL, . Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335–1374.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Huang JF, Yu ML, Lee CM, . Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: A 1386-patient study from Taiwan. Aliment Pharmacol Ther. 2007;25(9):1029–1037.
   Google Scholar
• Shiratori Y, Imazeki F, Moriyama M, . Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132(7):517–524.
   Google Scholar
• Yu ML, Lin SM, Chuang WL, . A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11(8):985–994.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kawata S, Tamura S, . Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129(2):94–99.
   Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967–972.
   PubMed Web of Science ®Google Scholar
• Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005;39(1 Suppl.):S3–S8.
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485–1492.
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, . Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1493–1499.
   PubMed Web of Science ®Google Scholar
• Akram M, Idrees M, Zafar S, . Effects of host and virus related factors on interferon-alpha+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients. Virol J. 2011;8:234.
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358(9286):958–965.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Wasserman R, Brooks L, . Changes in hemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11(3):243–250.
   Google Scholar
• Takaki S, Tsubota A, Hosaka T, . Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39(7):668–673.
   Google Scholar
• McHutchison JG, Manns MP, Brown Jr. RS, . Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol. 2007;102(4):880–889.
   Google Scholar
• Jen JF, Glue P, Gupta S, . Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22(5):555–565.
   Google Scholar
• Snoeck E, Wade JR, Duff F, . Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62(6):699–709.
   Google Scholar
• Reau N, Hadziyannis SJ, Messinger D, . Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;103(8):1981–1988.
   Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl. 1):S237–S244.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr., Morgan TR, . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355.
   PubMed Web of Science ®Google Scholar
• Abstracts of the Biennial Meeting of the International Association for the Study of the Liver, April 15–16, 2002 and the 37th Annual Meeting of the European Association for the Study of the Liver, April 18–21, 2002. Madrid, Spain. J Hepatol. 2002;36(Suppl. 1):1–298 ; PubMed 12051238.
   Google Scholar
• Bruchfeld A, Lindahl K, Schvarcz R, . Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis. Ther Drug Monit. 2002;24(6):701–708.
   PubMed Web of Science ®Google Scholar
• Lindahl K, Schvarcz R, Bruchfeld A, . Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat. 2004;11(1):84–87.
   Google Scholar